In November 2006, Embrex Inc, was acquired by the Animal Health division of Pfizer Inc. Embrex, Inc. develops and markets biological delivery technology and biological products to increase the productivity and profitability of the global poultry industry. Embrex has developed and commercialized a proprietary, automated in-the-egg injection system, which can inoculate 20,000 to 50,000 eggs per hour and eliminates the need for manual, post-hatch injection of certain vaccines. This proprietary system, called INOVOJECT, is designed to inject vaccines and other compounds in precisely calibrated volumes into targeted compartments within the egg. The Company has also developed, patented and commercialized a Viral Neutralizing Factor technology, which permits single-dose immunization of the avian embryo effective or the life of the bird.
